These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10422782)

  • 1. Superiority of platelet integrin GPIIb-IIIa receptor antagonist over aspirin in preventing cyclic flow reductions in the guinea pig middle cerebral artery.
    Kawano K; Ikeda Y; Kondo K; Umemura K
    Eur J Pharmacol; 1999 Jun; 374(3):377-85. PubMed ID: 10422782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
    Kawano KI; Hokamura K; Kondo K; Ikeda Y; Suzuki Y; Umemura K
    Eur J Pharmacol; 2001 Apr; 417(3):217-22. PubMed ID: 11334853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery.
    Kawano KI; Fujishima K; Ikeda Y; Kondo K; Umemura K
    J Cereb Blood Flow Metab; 2000 Jun; 20(6):988-97. PubMed ID: 10894182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban.
    Moriguchi A; Aoki T; Mihara K; Tojo N; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1094-101. PubMed ID: 14634048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of middle cerebral artery thrombosis by novel glycoprotein IIb/IIIa antagonist FK419 in guinea pig.
    Moriguchi A; Mihara K; Aoki T; Maeda M; Tojo N; Matsuoka N; Mutoh S
    Eur J Pharmacol; 2004 Sep; 498(1-3):179-88. PubMed ID: 15363993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
    Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
    Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates.
    Matsuno H; Kozawa O; Nagashima S; Kanamaru M; Uematsu T
    Br J Pharmacol; 1999 Jul; 127(5):1129-34. PubMed ID: 10455258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis.
    Kaku S; Umemura K; Mizuno A; Yano S; Suzuki K; Kawasaki T; Nakashima M
    Eur J Pharmacol; 1998 Mar; 345(2):185-92. PubMed ID: 9600636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
    Maeda M; Moriguchi A; Mihara K; Aoki T; Takamatsu H; Matsuoka N; Mutoh S; Goto T
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):108-18. PubMed ID: 15678117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the antithrombotic effects of FK633, GPIIb/IIIa antagonist, and aspirin in a guinea pig thrombosis model.
    Aoki T; Cox D; Senzaki K; Seki J; Tanaka A; Takasugi H; Motoyama Y
    Thromb Res; 1998 Feb; 89(3):129-36. PubMed ID: 9622041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis.
    Willette RN; Sauermelch CF; Rycyna R; Sarkar S; Feuerstein GZ; Nichols AJ; Ohlstein EH
    Stroke; 1992 May; 23(5):703-11. PubMed ID: 1605806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
    Azzam K; Cissé-Thiam M; Drouet L
    Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
    Ogawa T; Sugidachi A; Naganuma H; Asai F
    Thromb Res; 2000 Mar; 97(5):307-15. PubMed ID: 10709906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery.
    Kaida T; Matsuno H; Niwa M; Kozawa O; Miyata H; Uematsu T
    Thromb Haemost; 1997 Mar; 77(3):562-7. PubMed ID: 9066011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog.
    Rebello SS; Driscoll EM; Lucchesi BR
    Stroke; 1997 Sep; 28(9):1789-96. PubMed ID: 9303027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
    Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
    Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist.
    Damiano BP; Mitchell JA; Giardino E; Corcoran T; Haertlein BJ; de Garavilla L; Kauffman JA; Hoekstra WJ; Maryanoff BE; Andrade-Gordon P
    Thromb Res; 2001 Oct; 104(2):113-26. PubMed ID: 11672755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of TAK-029, a novel GPIIb/IIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys.
    Kawamura M; Tsuji N; Moriya N; Terashita Z
    Thromb Res; 1997 May; 86(4):275-85. PubMed ID: 9187016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.